Oleanolic Acid Reduces Hyperglycemia beyond Treatment Period with Akt/FoxO1-Induced Suppression of Hepatic Gluconeogenesis in Type-2 Diabetic Mice

• Xiao-Yi Zeng,

  Affiliation Molecular Pharmacology for Diabetes, Health Innovations Research Institute and School of Health Sciences, RMIT University, Melbourne, Victoria, Australia

  ⨯
• Yi-Ping Wang,

  Affiliation Molecular Pharmacology for Diabetes, Health Innovations Research Institute and School of Health Sciences, RMIT University, Melbourne, Victoria, Australia

  ⨯
• James Cantley,

  Affiliation Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia

  ⨯
• Tristan J. Iseli,

  Affiliation Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia

  ⨯
• Juan Carlos Molero,

  Affiliation Molecular Pharmacology for Diabetes, Health Innovations Research Institute and School of Health Sciences, RMIT University, Melbourne, Victoria, Australia

  ⨯
• Bronwyn D. Hegarty,

  Affiliation Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia

  ⨯
• Edward W. Kraegen,

  Affiliation Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia

  ⨯
• Yang Ye,

  Affiliation Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  ⨯
• Ji-Ming Ye

  * E-mail: jiming.ye@rmit.edu.au

  Affiliations Molecular Pharmacology for Diabetes, Health Innovations Research Institute and School of Health Sciences, RMIT University, Melbourne, Victoria, Australia, Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  ⨯